ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway by Shen, Y-L et al.
 Shen, Y-L, Jiang, Y-P, Li, X-Q, Wang, S-J, Ma, M-H, Zhang, C-Y, Zhu, J-Y, 
Rahman, K, Zhang, L-J, Luan, X and Zhang, H
 ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by 
Inhibiting CXCL6/JAK/STAT3 Signaling Pathway
http://researchonline.ljmu.ac.uk/id/eprint/12531/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Shen, Y-L, Jiang, Y-P, Li, X-Q, Wang, S-J, Ma, M-H, Zhang, C-Y, Zhu, J-Y, 
Rahman, K, Zhang, L-J, Luan, X and Zhang, H (2020) ErHuang Formula 
Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting 
CXCL6/JAK/STAT3 Signaling Pathway. Frontiers in Pharmacology, 10. ISSN 
LJMU Research Online
Frontiers in Pharmacology | www.frontiers
Edited by:
Adolfo Andrade-Cetto,
National Autonomous
University of Mexico, Mexico
Reviewed by:
Yuntao Dai,
Wangjing Hospital of China Academy
of Chinese Medical Sciences, China
Jun-sheng Tian,
Shanxi University, China
*Correspondence:
Li-Jun Zhang
zhanglijun0407@163.com
Xin Luan
luanxin@shutcm.edu.cn
Hong Zhang
hqzhang51@126.com
†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Ethnopharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 07 August 2019
Accepted: 09 December 2019
Published: 24 January 2020
Citation:
Shen Y-L, Jiang Y-p, Li X-Q,
Wang S-J, Ma M-H, Zhang C-Y,
Zhu J-Y, Rahman K, Zhang L-J,
Luan X and Zhang H (2020) ErHuang
Formula Improves Renal Fibrosis in
Diabetic Nephropathy Rats by
Inhibiting CXCL6/JAK/STAT3
Signaling Pathway.
Front. Pharmacol. 10:1596.
doi: 10.3389/fphar.2019.01596
ORIGINAL RESEARCH
published: 24 January 2020
doi: 10.3389/fphar.2019.01596ErHuang Formula Improves Renal
Fibrosis in Diabetic Nephropathy
Rats by Inhibiting CXCL6/JAK/STAT3
Signaling Pathway
Yu-Li Shen1,2†, Yi-ping Jiang3†, Xiao-Qin Li1,4†, Su-Juan Wang5, Ming-Hua Ma6,
Chun-Yan Zhang7, Jian-Yong Zhu7, Khalid Rahman8, Li-Jun Zhang1*, Xin Luan1,2*
and Hong Zhang1*
1 Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai,
China, 2 Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, 3 Department of
Pharmacognosy, School of Pharmacy, Second Military Medical University, Shanghai, China, 4 School of Pharmacy, Chengdu
University of Traditional Chinese Medicine, Chengdu, China, 5 Department of Drug Preparation, Hospital of TCM and Hui
Nationality Medicine, Ningxia Medical University, Wuzhong, China, 6 Department of Pharmacy, Yangpu Hospital, Tongji
University School of Medicine, Shanghai, China, 7 Central Laboratory, Seventh People's Hospital, Shanghai University of
Traditional Chinese Medicine, Shanghai, China, 8 School of Pharmacy and Biomolecular Sciences, Faculty of Science,
Liverpool John Moores University, Liverpool, United Kingdom
Diabetic nephropathy (DN) is one of the main causes of renal ﬁbrosis and is associated
with high morbidity and mortality. Traditional Chinese Medicine (TCM) therapy has a long
history of usage in a clinical setting and its usage is increasing. ErHuang Formula (EHF), a
Chinese herbal compound, has been clinically used in treating DN for more than 30 years.
However, its mechanism of action is still unknown. This study was conducted to evaluate
the effect of EHF on renal ﬁbrosis in a DN rat model and explore its underlying mechanism.
The DN rat model was established by high-sugar-fat diet combined with a single
intraperitoneal injection of streptozotocin (STZ), and EFH extract (4, 2, 1 g/kg d−1) was
administered orally for 8 weeks. The biochemical parameters (blood glucose, weight, Scr,
BUN, UA, U-Alb and UAE) were analyzed. The pathological changes in renal tissue were
observed by histological staining with H&E and Masson. The effect of EHF on the
proliferation of NRK-49F cells was examined by CCK-8 assay and the levels of several
inﬂammation and ﬁbrosis related cytokines (IL-6, TNF-a, TGF-b1, Collagen I/III, MMP2/9)
in serum and NRK-49F cell culture supernatants were detected by enzyme-linked
immunoassay (ELISA). The mRNA levels of CXCL6, CXCR1, Collagen I/III, MMP2/9 in
renal tissue were also measured by quantitative RT-PCR. Furthermore, the protein
expression of PCNA, Collagen I/III, MMP2/9, CXCL6, CXCR1, p-STAT3, STAT3 in renal
tissue and NRK-49F cells were determined by western blot. EHF improved the abnormal
biochemical parameters and ameliorated the abnormal histology and ﬁbrosis of renal
tissue in a dose-dependent manner. EHF inhibited NRK-49F proliferation and decreased
the expressions of inﬂammation and ﬁbrosis related factors both in vitro and in vivo.
Interestingly, the levels of Collagen I/III, PCNA, MMP2/9 and p-STAT3 were positively
correlated with CXCL6. The amelioration of renal ﬁbrosis in DN by EHF is related toin.org January 2020 | Volume 10 | Article 15961
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Frontiers in Pharmacology | www.frontiersCXCL6/JAK/STAT3 signal pathway, which is associated with inﬂammation and ﬁbrosis of
the tissue. These ﬁndings may have clinical implications for the treatment of DN.Keywords: ErHuang formula, renal ﬁbrosis, diabetic nephropathy, mechanism, JAK/STAT3INTRODUCTION
Diabetic nephropathy (DN) is regarded as a microvascular
complication of diabetes and represents the leading cause of
cardiovascular disease and end-stage chronic kidney disease
(Nagaishi et al., 2016). The incidence and prevalence of DN is
growing signiﬁcantly, and approximately 40% patients with
diabetes have developed DN and 9% of the adult population is
affected globally (Simpson et al., 2016; Alicic et al., 2017) and it
has become one of the major threats to public health worldwide.
Currently, the treatments of DN include intensive management
of lipid, glycemic and blood pressure control as well as renin–
angiotensin–aldosterone system blockade (Rossing et al., 2018).
Nevertheless, none of these treatments are ideal for the treatment
of DN and there is an urgent need to explore alternative
therapeutic strategy.
Inﬂammation is considered a critical initiator in the
pathophysiology of DN and several lines of evidence have
shown that some cytokines and chemokines, such as nuclear
factor-kB (NF-kB), interleukin-6 (IL-6), tumor necrosis factor-a
(TNF-a), transforming growth factor-b (TGF-b) and Soluble C-
X-C chemokine ligand (CXCLs), play a vital role in the
inﬂammatory response (Wada and Makino, 2013; Talsma
et al., 2018). In addition, ﬁbrosis related factors matrix
metalloproteinases (MMPs) and collagen are also of important
factors in DN. Therefore, controlling pro-inﬂammatory or pro-
ﬁbrotic mediators might be effective in the treatment of DN.
At present, several pathways are found to be associated
with DN progression, such as Janus kinase-signal transducer
and activator of transcription (JAK/STAT), PI3K/Akt, Wnt/b-
catenin and microRNA-137/Notch1 signaling pathway (Li et al.
2015; Brosius et al., 2016; Han et al., 2018). Among these,
JAK/STAT is the prominent pathway which can stimulate
excessive proliferation and growth of glomerular mesangial
cells, leading to DN (Marrero et al., 2006). Furthermore,
increasing the activity of STAT3 or phosphorylated STAT3n; CXCLs, C-X-C chemokine ligand;
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in.org 2(p-STAT3) can promote the proliferation of renal interstitial
ﬁbroblasts and the progression of renal ﬁbrosis (Koike et al.,
2014). Hence, it is reasonable to expect that inhibition of DN
associated signaling pathways can improve the progression of
renal ﬁbrosis in DN.
Traditional Chinese Medicine (TCM) has been used for
thousands of years for the treatment of a variety of disorders
(Wen et al., 2017). This has led to clinical observations which
have provided evidence of safety and efﬁcacy of TCM usage
including its use in the treatment of DN (Yan et al., 2016; Zhao
et al., 2018).
Erhuang Formula (EHF), a Chinese herbal formula, is a
hospital preparation of Shanghai Seventh People's Hospital,
and has been used for more than 30 years for the treatment of
kidney disease (Zhang et al., 2017). EHF is composed of Astragali
radix, Rheiradix etrhizoma, Trigonellae semen, Achyranthis
bidentatae radix, Vaccariae semen, Smilacis glabrae rhizoma,
Curcumae rhizome (Table 1). EHF shows an obvious
improvement in patients with chronic renal failure (CRF). We
has reported previously that EHF ameliorated renal damage in
adenine-induced CRF rats, and the mechanisms might involve in
the inhibition of inﬂammation and ﬁbrotic responses (Zhang
et al., 2017). The two main Chinese medicines comprising EHF,
A. radix (Huangqi) and R. etrhizoma (Dahuang) have been
reported for the treatment of DN (Xu et al., 2011; Liao et al.,
2017). However, it is unclear whether EHF exerts an effect on
DN. Herein, the high-sugar-fat combined with streptozotocin
(STZ)-induced DN rat model and a normal rat kidney ﬁbroblast
cell line NRK-49F were used to evaluate the effect of EHF on DN
and explore its underlying mechanism of action.TABLE 1 | Different components of EHF.
Pharmaceutical
name
Botanical plant
name
Family Medicinal
part
Ratio
Astragali radix Astragalus
membranaceus
(Fisch.) Bunge
Leguminosae Root 6
Rheiradix et
rhizoma
Rheum palmatum L. Polygonaceae Root and
Rhizome
3
Trigonellae
semen
Trigonella foenum-
graecum L.
Leguminosae Seed 2
Achyranthis
bidentatae radix
Achyranthes
bidentata Blume
Amaranthaceae Root 3
Vaccariae semen Vaccaria segetalis
(Neck.) Garcke ex
Asch.
Caryophyllaceae Seed 2
Smilacis glabrae
rhizoma
Smilax glabra Roxb. Liliaceae Rhizome 6
Curcumae
rhizome
Curcuma phaeocaulis
Valeton
Zingiberaceae Rhizome 2January 2020 | Volume 10 | Article 1596
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Preparation of Erhuang Formula
Erhuang Formula (EHF) consists of seven Chinese herbal
medicines, viz. Huang Qi, Zhi Da Huang, Hu Lu Ba, Huai Niu
Xi, Wang Bu Liu Xing, Tu Fu Ling and E Zhu, which was
prepared and purchased (Batch Number: 1412245, 1410211,
2014112503, 1411003, 2014120401, 2014112703, and 1408012,
respectively) from Shanghai Chinese Medicine Pharmaceutical
Technology Ltd. (Shanghai, China), as reported earlier (Zhang
et al., 2017). The airdried herbs identiﬁed by authority were
powdered and subjected to reﬂux extraction with 10 times water
for 1 h. The aqueous extracts were ﬁltered and collected. The
extraction was repeated twice with the method introduced above,
and then all the extracts were evaporated to dryness under
reduced pressure. Finally, 1 g of prepared EHF extract was
equivalent to 5 g of original crude herbs. The pulverized EHF
extracts were dispersed and dissolved in stilled water for
animal experiments.
High Performance Liquid
Chromatography/Mass Spectrometry
(HPLC/MS)
The compounds in EHF were analyzed by HPLC/MS, and the
speciﬁc method of operation was reported previously (Zhang
et al., 2017). An Agilent 1100 HPLC system and DAD and an LC/
MSD Trap XCT ESI mass spectrometer (Agilent Technologies,
MA, USA) were used for analysis. The separation was performed
on a GS-120-5-C18-BIO chromatographic column (5 µm, 250 ×
4.6 mm i.d.) with the column temperature set at 35 °C. A linear
gradient elution of A (0.1% formic acid water) and B
(acetonitrile) was used with the gradient procedure as follows:
0 min, B 5%, to 60 min B 40% (v/v). The ﬂow rate was 1.0 ml/min
and the injection volume was 10 µl. DAD was on and the target
wavelength was simultaneously set at 210 nm. The split ratio to
the mass spectrometer was 1:3. The acquisition parameters for
negative ion mode were: collision gas, ultra-high purity helium
(He), nebulizer gas (N2), 35 psi, drying gas (N2), 10 l/min, drying
temperature, 350°C, HV, 3500 V, mass scan range, m/z 100–
2,200, target mass, 500 m/z, compound stability, 100%, trap drive
level, 100%. All the data were analyzed by Chemstation software.
Animal Experiments
Animal Model Preparation
Male SD rats (160–200 g) were obtained from Shanghai Sippr BK
Laboratory Animals Ltd. (Shanghai, China). After feeding high-
sugar-fat diet (67% basic feed, 10% lard, 20% sugar, 2.5%
cholesterol, and 0.5% sodium cholate) for 8 weeks, the rats
were given a single intraperitoneal injection of 35 mg/kg
streptozotocin (STZ) (Sigma, S0130, dissolved in 0.01 M citrate
buffer, pH 4.5). After 72 h, the rats with fasting and random
blood glucose reading of above 13.8 mmol/l and 16.7 mmol/l,
respectively, and displaying glycosuria as ++++ were considered
diabetic. The DN rat was established when the uromicroprotein
exceeded 30 mg/day, this occurred four weeks after STZ injection
(Cao et al., 2016).Frontiers in Pharmacology | www.frontiersin.org 3Experimental Groups and Administration
The DN model rats were randomly divided into DN model
group, positive group (Metformin [H44023514], 300 mg/kg),
EFH high (4 g/kg), middle (2 g/kg) and low (1 g/kg) dose group.
A control group without any treatment was also established and
each group contained six rats. The oral gavage of EHF was given
once per day at a dose of 10 ml/kg for 8 weeks, while rats in DN
model group and control group were orally gavaged daily with
equivalent volumes of distilled water. The weight and blood
glucose measurements were performed weekly for each group.
Sample Collection
After 8 weeks of EHF administration, urine specimen, blood
samples from rat heart and renal tissues were collected and kept
for corresponding examination. The urinary albumin
concentration (U-Alb), uric acid (UA), urine albumin
excretion (UAE), serum creatinine (Scr) and serum urea
nitrogen (BUN) and were measured by automatic biochemical
analyzer. The level of IL-6, TNF-a, TGF-b1, Collagen I, Collagen
III, MMP2 and MMP9 in blood were detected by enzyme linked
immunosorbent assay (Elisa). The expression of CXCL6,
CXCR1, MMP2/9, Collagen I/III, TGFb-1, JAK-STAT in renal
tissues was determinated by quantitative real-time reverse
transcription polymerase chain reaction (qRT-PCR) and
Western blotting.
Cell Culture
Normal rat kidney ﬁbroblast cell line NRK-49F cells were
obtained from the Shanghai Cell Bank, Chinese Academy of
Sciences (Shanghai, China) and cultivated in Dulbecco's
Modiﬁed Eagle's Medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) and 1% penicillin–streptomycin
solution at 37 °C in 5% CO2 incubator. The cells were
observed as adherent cells under the microscope, and the rate
of trypan blue staining living cells was over 95%.
CCK-8 Assay
The CCK-8 assay was used to evaluate the anti-proliferation
effect of EHF on NRK-49F cells. NRK-49F cells were seeded at a
density of 3 × 103 cells in 100 µl into each well of 96-well plates.
After incubation at 37 °C overnight, the samples were divided
into control group and experiment groups. The control group
was treated with cell culture, while the experiment groups were
treated with EFH in 0.01, 0.05, 0.1, 0.25, 0.5, 1 mg/ml. The CCK-
8 reagent and serum-free solution (1:10) medium was then added
to each well at each time point (0, 24, 48 and 72 h), followed by
incubation for 1 h at 37 °C in 5% CO2. The optical density (OD)
at 450nm was quantiﬁed using Elisa and the survival rate was
calculated using the following equation: survival rate (%) =
ODTest/ODControl × 100%.
Lentivirus Transfection
The NRK-49F cells were seeded in 6-well plates, grown overnight
and transfected with CXCL6 overexpression lentivirus
(GeneChem, Shanghai, China) to investigate the regulatory
role of CXCL6. All of the transfections were performed usingJanuary 2020 | Volume 10 | Article 1596
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Scientiﬁc, Inc.) according to the manufacturer's instructions. A
blank vector lentivirus was used as a negative control (NC). The
expression of CXCL6 in cells following transfection was
conﬁrmed by Western blotting and qRT-PCR.
Quantitative Real-Time Reverse
Transcription Polymerase Chain Reaction
(qRT-PCR) Analysis
Total RNA was extracted from renal tissues or NRK-49F cells
using Trizol reagent (Invitrogen Carlsbad, CA, USA). The SYBR
Green-based qRT-PCR (Thermo Fisher) was performed to
examine the relative CXCL6, CXCR1, MMP2/9, Collagen I/III,
TGFb-1, JAK-STAT relative mRNA level, which were
normalized with GAPDH. The primer sequences are listed in
Table 2.
Western Blotting Analysis
The tissue samples or cultured cells were lysed on ice for 30 min
in RIPA buffer (Beyotime), supplemented with protease inhibitor
cocktail (Roche Applied Science, Indianapolis, IN, USA). After
centrifugation (12,000g) at 4°C for 20 min, the supernatant was
harvested and the protein concentration was determined by
using BCA assay kit (Thermo Fisher Scientiﬁc). Protein
extracts were separated by sodium dodecyl sulfate–
polyacrylamide gel and electroblotted onto a nitrocellulose
membrane. To block the non-speciﬁc binding sites, the
membranes were incubated with 5% non-fat milk at room
temperature for 60 min, and then probed with primary
antibodies overnight at 4°C. After washing three times with
Tris-buffered saline with 0.1% Tween-20 (TBST), the
membranes were incubated with the horseradish peroxidase
(HRP)-conjugated secondary antibody (Beyotime, Shanghai,
China) at room temperature for 1 h. The speciﬁc proteins in
the blots were visualized by using enhanced chemiluminescence
(ECL, Millipore, Bredford, USA). The densities of the protein
bands were quantiﬁed using Image J software (NIH, USA).
ELISA
The serum from rats and supernatants from cell culture were
assayed for IL-6, TNF-a, TGF-b1, Collagen I, Collagen III,
MMP2 and MMP9 by using a commercially available enzyme-
linked immunosorbent assay (ELISA) according to the
manufacturer's instructions. ALL the Elisa kits were purchased
from Shanghai Maiye biological technology co., Ltd.Frontiers in Pharmacology | www.frontiersin.org 4Histology
The tissue samples were ﬁxed with 4% paraformaldehyde,
dehydration and embedded in parafﬁn. General histology was
visualized by hematoxylin and eosin (H&E) and Masson
staining. The stained tissues were observed under an optical
microscope, the renal ﬁbrosis and collage deposition were
estimated respectively.
Statistical Analysis
Statistical analysis was performed using SPSS 16.0 software and
ﬁgures were made by GraphPad Prism 5.0. All experimental data
were expressed as mean ± standard error (SEM) and analyzed
with One-Way ANOVA test followed by Dunnett's test. Values
of P <0.05 were considered to be signiﬁcant.
Statement
The experiments were carried out in accordance with the
principles of the Basel Declaration and recommendations
followed by guidelines set from The Canadian Council on
Animal Care. The protocol was approved by The Experimental
Animal Ethical Committee of Seventh People's Hospital of
Shanghai University of Traditional Chinese Medicine.RESULTS
Identiﬁcation of Ten Compounds in EHF
The ten compounds were identiﬁed by HPLC/MS as reported
previously (Zhang et al., 2017), including liquiritigenin,
farnesene, vaccarin, pachymic acid, cycloastragenol, astilbin, 3,
5, 6, 7, 8, 3, 4′-heptemthoxyﬂavone, physcion, emodin, and
curzerene. The detailed results were presented in the
Supplementary Materials.EHF Improved the Biochemical
Parameters in DN Rats
The high-sugar-fat combined with STZ-induced DN model rats
were used to investigate the effect of EHF on DN. The blood
glucose before and after administrating of EHF is presented in
Figure 1A. After the administration of EHF, the blood glucose
was signiﬁcantly decreased compared to the value prior to the
administration of EHF and much lower than that in model
group. The weight of rats in EHF groups improved markedly
compared with model group, as shown in Figure 1B.TABLE 2 | Gene primer pairs used for qRT-PCR.
Gene Forward Reverse
CXCL6 5' CTTAGCTCCAAGAATTAACC 3' 5' GGTCAAGACAAACATTATCC 3'
CXCR1 5' TCTTCCGCCAGGCATATAAAC 3' 5' TAGCAGACCAGCATGATGAAC 3'
MMP2 5' ACCAAGAACTTCCGACTATCC 3' 5' CTGAGCAATGCCATCAAAGAC 3'
MMP9 5' TCTCTACTGGGCATTAGGG 3' 5' GTGTCCGAGGAAGATACTTG 3'
Collagen I 5' TGTGTTGCTGAAAGACTACC 3' 5' TAGCACCAGAAATTCCTTCC 3'
Collagen III 5' GTCCACAGCCTTCTACAC 3' 5' TCCGACTCCAGACTTGAC 3'
GRAPDH 5' GGAGTCTACTGGCGTCTTCAC 3' 5' ATGAGCCCTTCCACGATGC 3'January 2020 | Volume 10 | Article 1596
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groups is displayed in Figure 1C. The level of Scr, BUN, UA, U-
Alb and UAE in the model group was signiﬁcantly increased and
Alb was decreased compared with the control group. As
expected, in EHF groups, the level of Scr, BUN, UA, U-Alb
and UAE was notably reduced compared with the model group,
and the reduced effect was dose-dependent while the level of Alb
was increased markedly.
EHF Improved the Abnormal Histology
in DN Rats
The changes in athology of renal tissues were observed by
histological staining with H&E and Masson to conﬁrm the
effect of EHF on DN. As demonstrated in Figures 2A and B,
compared with control group, the kidney tissues samples from
model group revealed typical damage, including glomerular
sclerosis, glomerular mesangial cell proliferation, glomerular
basement membrane thickening, tubular dilation and atrophy.
Masson staining showed severe collagen ﬁbrosis and
inﬂammatory cell invasion in model group compared withFrontiers in Pharmacology | www.frontiersin.org 5control group. After treatment with EHF, these abnormalities
were ameliorated differently the higher concentration of EHF
showed better improvement.
EHF Reduced the Expression of
Inﬂammation and Fibrosis Related
Cytokines in DN Rats
To explore the effect of EHF on DN rats, several inﬂammation
and ﬁbrosis related cytokines in serum were detected by ELISA.
As presented in Figure 3, in model group, the levels of IL-6,
TNF-a, TGF-b1, Collagen I, Collagen III, MMP2 and MMP9
were increased signiﬁcantly compared with the control group.
However, there was a sharp reduction of these cytokines
following treatment with different doses of EHF. The effect of
EHF at 4 g/kg was similar to the positive group and all p values
were less than 0.001, which was statistically signiﬁcant.
The mechanisms of EHF on DN rats were investigated by
determining the expression of several inﬂammation and ﬁbrosis
related cytokines in renal tissues, including CXCL6, CXCR1,
MMP2, MMP9, Collagen I, Collagen III, PCNA, STAT andFIGURE 1 | EHF improved the biochemical parameters in DN rats. (A) The blood glucose was measured pre- and after-administration EHF. *p < 0.05, ***p < 0.001
versus pre-administration, ###p < 0.001 versus control group. (B) The weight of rats in each group. **p < 0.01, ***p < 0.001 versus model group. (C) The level
of Scr, BUN, UA, U-Alb and UAE in each group was determined by automatic biochemical analyzer. *p < 0.05, **p < 0.01, ***p < 0.001 versus model group,
###p < 0.001 versus control group. n = 6.January 2020 | Volume 10 | Article 1596
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cytokines were signiﬁcantly upregulated both at mRNA and
protein levels compared with control groups. In contrast, the
level of these cytokines was reduced dramatically after
intragastrical administration of EHF in a dose-dependent manner.
EHF Inhibited the Proliferation of NRK-49F
Cells
As shown clearly in Figure 4, compared with the control group,
treatment with EHF more than 0.1 mg/ml for 24, 48 and 72h
resulted in a remarkable anti-proliferation in high-sugar (25
mmol/l) induced NRK-49F cells in a concentration- and time-
dependent manner.
EHF Decreased the Expression of CXCL6
and CXCR1 in NRK-49F Cells
The expression of CXCL6 and CXCR1 in high-sugar (25 mg/ml)
induced NRK-49F cells was evaluated by qRT-PCR and Western
blotting. After treating with EHF (0.1 mg/ml, 0.25 mg/ml, 0.5
mg/ml), the expression of both CXCL6 and CXCR1 wasFrontiers in Pharmacology | www.frontiersin.org 6signiﬁcantly inhibited, and the inhibitory effect displayed
concentration-dependent relationships (Figures 4B, 4D).
To further evaluate the effect of EHF on the expression of
CXCL6 and CXCR1, lentivirus was transfected into high glucose
(25 mM) induced NRK-49F cells to induce the overexpression of
CXCL6, and then the transfected NRK-49F cells were treated
with 0.5 mg/ml EHF. As shown in Figures 4C, the expression of
CXCR1 and CXCL6 was measured by qRT-PCR and Western
blotting. In the CXCL6 overexpression (OE) group, the levels of
CXCL6 and CXCR1 were signiﬁcantly increased. After treatment
with EHF (0.5 mg/ml), both CXCL6 and CXCR1 restored to
normal levels with different degrees, and had statistically
signiﬁcant differences compared with OE group.
EHF Reduced the Expression of
Inﬂammation and Fibrosis Related
Cytokines in NRK-49F Cells
To explore the underlying mechanism of anti-proliferation effect
on EHF, several related cytokines involved in inﬂammation and
ﬁbrosis were examined. ELISA results are presented in Figure 5,FIGURE 2 | EHF improved renal pathological features in DN rats. (A) H&E staining of renal tissues. (B) Masson staining of renal tissues. (a), control group (b), model
group (c), positive group (d), EHF-L (e), EHF-M (f), EHF-H.January 2020 | Volume 10 | Article 1596
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Collagen I, Collagen III, MMP2 and MMP9 in NRK-49F cell
culture supernatants were reduced signiﬁcantly compared with
the control group and the Western blotting analysis showed the
same results (Figure 5). The expressions of Collagen I, Collagen
III, PCNA, MMP2, MMP9 and p-STAT3 in NRK-49F cells were
signiﬁcantly decreased by treatment with EHF. However, the
expression of STAT3 had not been inﬂuenced and the
expressions of these relative cytokines were positively
correlated with the concentration of EHF.Frontiers in Pharmacology | www.frontiersin.org 7To further elucidate the mechanism of anti-proliferation
effect of EHF on NRK-49F cells, CXCL6 overexpression
lentivirus was used to increase the expression of CXCL6. The
inﬂammation and ﬁbrosis related cytokines were detected by
WB. The results displayed in Figure 5 indicate that in OE group,
the levels of Collagen I, Collagen III, PCNA, MMP2, MMP9 and
p-STAT3 were upregulated signiﬁcantly. Consistent with
previous results, EHF resulted in a remarkable inhibitory effect
on the expression of above cytokines. The high expression of
these cytokines induced by CXCL6 overexpression wasFIGURE 3 | EHF reduced the expression of inﬂammation and ﬁbrosis related cytokines in DN rats. (A) The levels of several inﬂammation and ﬁbrosis related
cytokines in peripheral blood were measured by ELISA. (B) Relative mRNA expressions of several inﬂammation and ﬁbrosis related cytokines were determined by
qRT-PCR. (C) The protein levels of several inﬂammation and ﬁbrosis related cytokines were examined by Western blotting. ***p < 0.001 versus model group,
###p < 0.001 versus control group. n = 6.January 2020 | Volume 10 | Article 1596
Shen et al. Chinese Medicine Improves Diabetic Nephropathysigniﬁcantly reduced by treatment with EHF (0.5 mg/ml).
Furthermore, there was no signiﬁcant difference in STAT3
level among these groups.DISCUSSION
A typical characteristic of DN is excessive deposition of
extracellular matrix (ECM) proteins in the mesangium andFrontiers in Pharmacology | www.frontiersin.org 8renal tubule-interstitium of the glomerulus and basement
membranes. ECM accumulation subsequently leads to the
expansion of mesangial matrix and thickening of the
glomerular and tubular basement membranes, eventually
resulting in renal ﬁbrosis, with high morbidity and mortality
rates (Hu et al., 2015; Zanchi et al., 2017). Therefore, indentation
of novel interventions to prevent the progression of DN is
extremely important. Recently, researches focused on the TCM
as a basic or complementary therapy for DN. EHF has been usedFIGURE 4 | EHF inhibited the proliferation of NRK-49F cells and decreased the expression of CXCL6 and CXCR1. (A) CCK8 analysis of NRK-49F cell proliferation.
(B), (D) The mRNA and protein expressions of CXCL6 and CXCR1 in different EHF dose groups were examined by qRT-PCR and Western blotting. GAPDH was
served as a loading control. (C), (E) The effect of 0.5 mg/ml EHF on the expression of CXCL6 and CXCR1 in CXCL6 overexpression NRK-49F cells was evaluated
by qRT-PCR and Western blotting. *p < 0.05, **p < 0.01, ***p < 0.001 versus control group.January 2020 | Volume 10 | Article 1596
Shen et al. Chinese Medicine Improves Diabetic Nephropathyto treat kidney diseases and renal ﬁbrosis with a history of more
than 30 years in clinical practice, and the ten compounds in EHF
has been identiﬁed as reported previously (Zhang et al., 2017). It
is necessary to further investigate its effect on DN and clarify its
underlying mechanism. Previous studies have showed that high
glucose could induce NRK-49F cells proliferation and activation
to myoﬁbroblasts (Chow et al., 2004; He et al., 2016). In the
present study, the high-sugar-fat combined with STZ-inducedFrontiers in Pharmacology | www.frontiersin.org 9DN rat model and NRK-49F cell were designed to evaluate the
effect of EHF and explore its suggested mechanism.
In DN rat model, after treating with EHF, the blood glucose,
weight and renal function markers (Scr, BUN, UA, UAC and
UAE), as well as renal pathological features were ameliorated.
The blood glucose, Scr, BUN, UA, UAC and UAE were lower in
EHF group than that in model group. In addition, histological
analysis showed that the degree of renal ﬁbrosis was signiﬁcantlyFIGURE 5 | EHF reduced the levels of inﬂammation and ﬁbrosis related cytokines in NRK-49F cells. (A, B) The levels of inﬂammation and ﬁbrosis related cytokines
were examined by ELISA and Western blotting. (C) The protein levels of key related cytokines in the control group, negative control (NC), CXCL6 overexpression
group (OE), NC+0.5 mg/ml EHF (NC+0.5) and OE+0.5 mg/ml (OE+0.5) were determined by Western blotting. *p < 0.05, **p < 0.01, ***p < 0.001 versus the
control group.January 2020 | Volume 10 | Article 1596
Shen et al. Chinese Medicine Improves Diabetic Nephropathyreduced after EHF treatment. Combined with above ﬁndings,
EHF had the potent possibility to prevent the development of
DN in DN rat model.
It was reported that inﬂammatory cytokines, such as IL-6 and
TNF-a, participate in the pathogenesis of DN (Navarrogonzález
et al., 2011). Both IL-6 and TNF-a could promote macrophage
activation and induce mesangial cell proliferation (Fan et al.,
2018). In this study, the level of IL-6 and TNF-a was lower in
EHF group compared to the model group, suggesting that EHF
could exert anti-inﬂammatory effect in the treatment of DN.
Moreover, proliferating cell nuclear antigen (PCNA) is closely
related to the synthesis of DNA and plays an important role in
the initiation of cell proliferation (Summary, 2017). In this
manuscript, PCNA protein level was strongly suppressed by
EHF, representing the anti-proliferative effect of EHF.
Meanwhile, other ﬁbrosis related cytokines were also
examined to explore the effect of EHF in renal ﬁbrosis. MMPs
were initially thought to have capacity to degrade ECM and anti-
ﬁbrosis effect. However, recent data suggests that the opposite
might be true, particularly gelatinases (MMP-2, -9), which are
the most relevant cytokines in the development of DN (Thrailkill
et al., 2009). MMP2 could promote ECM production and
accumulation in kidney cells (Tan and Liu, 2012), and MMP9
could stimulate renal ﬁbrosis and epithelial mesenchymal
transition (EMT) during obstructive nephropathy (Wang et al.,
2010). Current evidence demonstrate that EMT can enable the
tubular epithelial cells to obtain a mesenchymal phenotype
which results in their transition into myoﬁbroblasts (Zeisberg
and Kalluri, 2004). It is well known that collagen I, III are
interstitial matrix and ﬁbril-forming collagens, as well as majorFrontiers in Pharmacology | www.frontiersin.org 10components of ECM (Lei et al., 2014). Previous studies have
showed increased collagen I, III expression can result in
mesangial matrix expansion and glomerulosclerosis (Hu et al.,
2015). TGF-b1 is also closely correlated with progressive renal
ﬁbrosis. It is clear that TGF-b1 can not only induce ECM
deposition, but also stimulate ﬁbroblasts into myoﬁbroblasts
(Schnaper et al., 2003; Schrijvers et al., 2004). In addition,
TGF-b1 increases the expression of MMP-2 and collagen I, III.
In this study, MMP-2,-9, collagen I, III and TGF-b1 were
signiﬁcantly downregulated in EHF group compared with
model group, suggesting that EHF might treat DN through its
anti-ﬁbrosis effect.
It is worth pointing out that chemokines and their receptors
have recently been shown to play an important role in DN
(Ruster and Wolf, 2008; Duransalgado and Rubioguerra, 2014).
One example is CXCL16/CXCR6, whose activation could
accelerate tubulointersitial injury in DN via facilitate lipid
accumulation in tubular epithelial cells (Hu et al., 2016).
Interestingly, in our previous study, CXCL6 has been found to
have a vital role in promoting ﬁbrosis. CXCL6 might promote
ﬁbrosis-related factors to accelerate the development of renal
ﬁbrosis in DN by activating JAK/STAT3 signaling pathway (Sun
et al., 2019). It is well established that the role of JAK/STAT
signal pathway has been proven to contribute to the pathogenesis
of DN (Marrero et al., 2006). STAT3 is a critical downstream
regulator of JAK/STAT signal pathway. Increasing the activity of
phosphorylated STAT3 (p-STAT3) could promote the
proliferation of renal interstitial ﬁbroblasts and the progression
of renal ﬁbrosis. In the present study, the expressions of CXCL6
and its receptor CXCR1 were decreased remarkably afterFIGURE 6 | Flow diagram for suggested mechanisms of EHF on DN.January 2020 | Volume 10 | Article 1596
Shen et al. Chinese Medicine Improves Diabetic Nephropathytreatment with EHF both at mRNA and protein level, suggesting
that EHF could inhibit the expression of CXCL6/CXCR1.
Furthermore, the level of p-STAT3 was higher in CXCL6
overexpression group than control group while reduced
notably after treating with EHF, representing that the
expression of p-STAT3 could be regulated by CXCL6. Taken
as a whole, EHF might improve renal ﬁbrosis in DN rats by
inhibiting CXCL6/JAK/STAT3 signaling pathway.
In conclusion, this study conﬁrmed that EFH might improve
the renal ﬁbrosis and prevent the development of DN. The
possible mechanisms of EHF treating DN are summarized in
Figure 6. EHF may treat DN through its anti-inﬂammatory,
anti-proliferation and anti-ﬁbrosis effect. Furthermore, EHF
might improve renal ﬁbrosis and prevent the development of
DN by inhibiting CXCL6/JAK/STAT3 signaling pathway. Thus,
EHF may be considered as a novel effective agent in the
treatment of ﬁbrotic kidney disorders and however, further
studies are required in a clinical setting to support
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